الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 168 |  |  |
| | | from | 168 | | |
Abstract
Aim of the work
The aim is to demonstrate the level of circulating VEGF in patients with congestive heart failure regardless its etiology that may provide scientific bases for progression into further clinical trials in the treatment of congestive heart failure.
The mean results of this study were:
1- There was no statistical significance difference of the VEGF in patients with congestive heart failure as a whole versus controls. However taking the etiology of congestive heart failure into account, there was a marked reduction of the level of VEGF in the patients with ischemic heart failure versus controls (p= 0.004).
2- Among the patients group, the level of VEGF was not influenced by the functional grade of heart failure, however there was a statistically significant positive correlation between VEGF and ejection fraction (p < 0.04).
3- The circulating VEGF in the patients with congestive heart failure was influenced by age, gender, smoking and diastolic blood pressure. It was lower in males (p= 0.02), elders (p= 0.01), smokers (p= 0.02) and higher diastolic blood pressure (p= 0.05).
Conclusion and recommendations
The circulating VEGF was not changeable in the patients with congestive heart failure as a whole; however it was markedly reduced in patients with ischemic heart failure. VEGF showed a significant reduction among male gender, elders, smokers and patients with higher diastolic blood pressure. It had a statistically significant positive correlation with ejection fraction, however not affected by functional grading of heart failure according to NYHA functional classification.
We recommend more studies to clarify the regulatory mechanisms of VEGF in ischemic heart failure and to validate its use in therapeutic angiogenesis especially in patients with myocardial ischemia not candidate for coronary revascularization.